Interestingly, the inhibitory effect of L1-11A on ovarian cancer cell growth synergized with radioimmunotherapy based on the 67Cu-labelled anti-L1CAM antibody chCE7 [96], thus implying the feasibility of combinatorial L1CAM-targeted treatments. This evidence concerns the gene L1CAM and ovarian carcinoma.